-+ 0.00%
-+ 0.00%
-+ 0.00%

Inhibikase Therapeutics FY2025 net loss widens 75.39% to $48 million; R&D expenses climb 73.13% to $30 million

Reuters·03/26/2026 20:05:00

Please log in to view news